Related Experiment Videos
Prostaglandin E1 in suspected ductus dependent cardiac malformation
Archives of Disease in Childhood
|November 1, 1984
Summary
Low-dose prostaglandin E1 (alprostadil) effectively treats neonates with critical congenital heart defects. This safe, low-dosage regimen is recommended for early administration before transfer to specialized cardiac centers.
Area of Science:
- Neonatal Cardiology
- Pediatric Pharmacology
- Congenital Heart Disease
Background:
- Major duct-dependent cardiac defects pose critical risks to neonates.
- Timely intervention is crucial for managing these severe conditions.
Purpose of the Study:
- To determine an effective and safe dosage regimen of prostaglandin E1 (alprostadil) for neonates.
- To establish early treatment protocols for suspected duct-dependent cardiac defects.
Main Methods:
- Intravenous infusions of prostaglandin E1 (alprostadil) administered to 52 neonates.
- Doses ranged from 0.005 to 0.1 micrograms/kg/minute.
- Clinical improvement and side effects were monitored at varying dosages.
Main Results:
- Effective clinical improvement observed across all tested dosages.
- Side effects appeared to be dose-dependent.
- No serious adverse events were noted at low dosages (0.005–0.01 micrograms/kg/minute).
Conclusions:
- Low-dose prostaglandin E1 (alprostadil) is effective and safe for neonates with duct-dependent cardiac defects.
- A low-dosage regimen should be initiated promptly upon diagnosis, prior to transfer to a pediatric cardiac center.